Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/20.500.12104/44269
Título: Rheology of cetyltrimethylammonium tosilate-water system. 1. Relation to phase behavior
Autor: Robles-Vasquez, O.
Corona-Galvan, S.
Soltero, J.F.A.
Puig, J.E.
Tripodi, S.B.
Valles, E.
Manero, O.
Fecha de publicación: 1993
Resumen: Dynamic and steady-shear rheological measurements of the AOT/water lamellar liquid crystalline phase are reported as a function of surfactant concentration. Dynamical measurements indicate that the AOT/water lamellar phase behaves as a weak gel; i.e., both the elastic and the loss moduli, G? and G? are nearly independent of frequency (?) and G? is an order of magnitude greater than G? in the range 10-2 to 102 s-1. Complex and dynamic viscosities decrease with frequency as ?-1. Steady shear measurements demonstrate a shear thinning behavior with ? ? ?-1 but ? does not tend to a Newtonian plateau at low shear rates. The measured material functions (G?, ?*, and ?) go through a minimum at around 50 wt% AOT. This minimum is explained in terms of attractive and repulsive colloidal forces in the bilayers and in terms of interactions among the liquid crystalline microdomains. " 1993 Academic Press. All rights reserved.",,,,,,"10.1006/jcis.1993.1368",,,"http://hdl.handle.net/20.500.12104/44269","http://www.scopus.com/inward/record.url?eid=2-s2.0-43949175443&partnerID=40&md5=302fad27e58b9ff5e066af7ab993a8d6",,,,,,"1",,"Journal of Colloid And Interface Science",,"65
71",,"160",,"Scopus",,,,,,,,,,,,"Rheology of Lyotropic Liquid Crystals of Aerosol OT. II. High Concentration Regime",,"Article" "46022","123456789/35008",,"Pallás, M., Deparment of Pharmacology and Medical Chemistry, Faculty of Pharmacy School of Pharmacy, Unitat de Farmacologia i Farmacognòsia Facultat de Farmàcia, Avda Diagonal 643, 08028-Barcelona, Spain; Ortuño-Sahagún, D., Institute of Research in Biomedical Sciences (IICB), CUCS, University of Guadalajara, Sierra Mojada No. 950, Col. Independencia, Guadalajara, 44340 Jalisco, Mexico; Andrés-Benito, P., Deparment of Pharmacology and Medical Chemistry, Faculty of Pharmacy School of Pharmacy, Unitat de Farmacologia i Farmacognòsia Facultat de Farmàcia, Avda Diagonal 643, 08028-Barcelona, Spain; Ponce-Regalado, M.D., Laboratory of Neural Development and Regeneration, Institute of Neurobiology, Department of Cellular and Molecular Biology, Zapopan, 44600 Jalisco, Mexico; Rojas-Mayorquín, A.E., Department of Environmental Sciences, Institute of Neurosciences, CUCBA, 45100 Jalisco, Mexico, Department of Basic Research, National Institute of Geriatrics (INGER), Periforico Sur No. 2767, 10200 México, D.F., Mexico",,"Pallas, M.
Ortuno-Sahagun, D.
Andres-Benito, P.
Ponce-Regalado, M.D.
Rojas-Mayorquin, A.E.",,"2014",,"Resveratrol has been extensively investigated and has been demonstrated to have antioxidant properties, cancer chemopreventive activity, and the capacity to modulate the hepatic synthesis of triglycerides and cholesterol, among others well established actions. A noteworthy feature of resveratrol is its ability to cross the blood-brain barrier and to exhibit neuroprotective actions, mainly by their capacity to regulate redox pathways as well as the Sirtuin (SIRT) system, which in turn modulates gene transcription, controlling inflammation and apoptosis in the brain. Lately, evidence is accumulating with respect to the synergic effect of resveratrol with antiepileptic drugs and also its antiepileptic activity in various models of seizures. We discuss here recent evidence that strongly suggests that resveratrol acts as an anticonvulsant agent and could be a very effective method for reducing damage in neural tissue and even for preventing seizure development in coadjuvant antiepileptic therapy.",,,,,,"10.2741/4267",,,"http://hdl.handle.net/20.500.12104/44243","http://www.scopus.com/inward/record.url?eid=2-s2.0-84904603910&partnerID=40&md5=6fe066e57abd83c3315699a15ca0cfc4",,,,,,"7",,"Frontiers in Bioscience - Landmark",,"1057
1064",,"19",,"Scopus
WOS",,,,,,"Epilepsy Model; Neuroprotection; Nutraceutic; Resveratrol; Review",,,,,,"Resveratrol in epilepsy: Preventive or treatment opportunities?",,"Article" "46032","123456789/35008",,"Tamayo, J.M., Departamento de Psiquiatría, Universidad CES, Medellín, Colombia; Rosales-Barrera, J.I., Facultad de Ciencias de la Salud, Universidad Anahuac, Edo. de México, Mexico; Villaseñor-Bayardo, S.J., Universidad de Guadalajara y Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico; Rojas-Malpica, C., Departamento de Salud Mental, Universidad de Carabobo, Valencia, Venezuela",,"Tamayo, J.M.
Rosales-Barrera, J.I.
Villasenor-Bayardo, S.J.
Rojas-Malpica, C.",,"2011",,"Major depressive disorder (MDD) is a prevalent and costly disease that is usually associated with high rates of disability. The target for the treatment of MDD is to achieve and maintain remission or complete control of depressive symptoms by the choice of an effective antidepressant. Sometimes, despite evidence based-treatment, it is possible that the patient does not have a favorable response. Although there is an increasing number of antidepressants available to treat depression, approximately half of the patients do not respond and two-thirds do not achieve remission after first-line treatment. In these cases we refer to treatment-resistant depression (TRD) as is defined in an article in this issue of Salud Mental. The TRD is one of the most complex conditions in psychiatry from the therapeutic point of view due to different definitions, algorithms, and response criteria, especially in Latin America where the procedures based on regional needs and consensus are scarce and not always based on evidence. It was conducted a systematic review using several databases such as MEDLINE, PsycINFO, EMBASE, the Cochrane Library and LILACS from 1949 to March 2011 crossing terms which allowed the inclusion of relevant articles in the management of the TRD. Unfortunately, the original publications in Latin America are often based on TRD case report, so the results and conclusions of this review have been based entirely on Anglo-Saxon scientific production. The therapeutic strategies used in the TRD are many, and include combinations of antidepressants or other psychotropic agents, in some cases addition of psychotherapy and, in extreme cases, neurostimulation techniques such as electroconvulsive therapy (ECT). The study Sequenced Treatment Alternatives to Relieve Depression (STARD) is the largest trial of treatment for MDD conducted in real practice settings, and the first to study remission as a measure of pre-defined primary outcome. It consists of four different stages of resistance. It is clear that there are diminishing remission rates as the number of treatment trials increases. The strategies include: antidepressant dose optimization, addition of medications like thyroid hormone, lithium, or nutritional supplements, a combination of antidepressants, and addition of second-generation antipsychotics (SGAs). Evidence suggests that remission rates can be from 25% to 50%, although with some differences among the drugs recommended. Evidence supports the use of SGAs for increasing the level of remission of new-generation antidepressants, although neither the profit nor the long-term benefits of this strategy have been well established. Neuro-modulation techniques include ECT, repetitive transcranial magnetic stimulation (rTMS), deep brain stimulation (DBS), and vagus nerve stimulation (VNS). ECT remains a first line option for the treatment of DRT with response rates ranging from 50% to 89%. Finally, the effectiveness of cognitive-behavioral therapy (CBT) in the management of the DRT could be a useful alternative when practiced in conjunction with any of the pharmacological strategies. However, further studies are needed to recommend it as first line treatment.",,,,,,,,,"http://hdl.handle.net/20.500.12104/44253","http://www.scopus.com/inward/record.url?eid=2-s2.0-84859832935&partnerID=40&md5=e1ab2a0f65455aa5f9e7e6bde2dafadd",,,,,,"3",,"Salud Mental",,"257
266",,"34",,"Scopus",,,,,,"Antidepressants; Antipsychotics; Neurostimulation; Refractory-depression; Resistant-depression",,,,,,"Review of medical literature on the management of treatment-resistant/refractory depression [Revisión de la literatura médica sobre el manejo de las depresiones resistentes/refractarias al tratamiento]",,"Article" "46045","123456789/35008",,"Soltero, J.F.A., Departamento de Ingeniería Química, Universidad de Guadalajara, Boul. M. García Barragan #1451, Guadalajara, Jalisco 44430, Mexico; Puig, J.E., Departamento de Ingeniería Química, Universidad de Guadalajara, Boul. M. García Barragan #1451, Guadalajara, Jalisco 44430, Mexico; Manero, O., Instituto de Investigaciones en Materiales, Universidad Nacional Autónoma de México, Apdo. Postal 70-360, México D.F. 04510, Mexico; Schulz, P.C., Departamento de Química y de Ingeniería Química, Universidad Nacional del Sur, Bahía Blanca 8000, Argentina",,"Soltero, J.F.A.
Puig, J.E.
Manero, O.
Schulz, P.C.",,"1995",,"The partial phase behavior of CTAT/water is investigated here as a function of temperature by WAXS, DSC, polarizing microscopy, conductometry, 1H-NMR, and FTIR spectroscopy. Oscillatory strain and temperature sweeps are also reported. The Krafft temperature (TK) of CTAT/water is 23°C. Below this value, triclinic crystals of CTAT coexist with an isotropic solution. Above TK and at low concentrations, spherical micellar solutions are Newtonian and exhibit low viscosities. At higher concentrations (ct), cylindrical micelles form and viscosity increases dramatically with CTAT concentration, but no elastic effects are noticed. When micelles are long enough to entangle (0.9-27 wt % at 25°C), clear viscoelastic solutions form. At higher concentrations and up to 47 wt %, an hexagonal phase appears. This phase exhibits yield stress and viscoelasticity. At higher concentrations, a nonelastic, viscous solid paste forms. Micellar solutions and hexagonal phase depicts three regimes of viscoelasticity with temperature. These regimes are bounded by Tk and by the temperature (T?) at which the system exhibits its main relaxation time. T? moves to lower temperatures as CTAT concentration increases indicating that the main relaxation time decreases upon increasing concentration. " 1995 American Chemical Society.
URI: http://hdl.handle.net/20.500.12104/44266
http://www.scopus.com/inward/record.url?eid=2-s2.0-0001138884&partnerID=40&md5=591079288243995b8a47eb75cfddc226
http://dx.doi.org/10.1021/la00009a013
Aparece en las colecciones:Producción científica UdeG

Ficheros en este ítem:
No hay ficheros asociados a este ítem.


Los ítems de RIUdeG están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.